Standard Biotools (LAB) Cash from Investing Activities (2010 - 2026)

Standard Biotools (LAB) has reported Cash from Investing Activities for 17 consecutive years, with $14.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 47.62% year-over-year to $14.4 million in Q2 2026; TTM through Jun 2026 was $190.8 million, a 415.99% increase from a year earlier, with the FY2025 full-year figure at $27.4 million, down 92.45% from the prior year.
• Cash from Investing Activities was $14.4 million for Q2 2026 at Standard Biotools, down from $191.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $318.1 million in Q1 2024 and troughed at -$138.2 million in Q2 2022.
• A 5-year average of $29.3 million and a median of $14.5 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 1419.96% in 2022 and jumped 5071.66% in 2023, its largest moves.
• Over 5 years, Cash from Investing Activities stood at $40.2 million in 2022, then sank by 132.59% to -$13.1 million in 2023, then surged by 296.13% to $25.7 million in 2024, then slumped by 131.25% to -$8.0 million in 2025, then surged by 279.2% to $14.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $14.4 million (Q2 2026), $191.1 million (Q1 2026), and -$8.0 million (Q4 2025), per Business Quant data.